Or­biMed, RA Cap­i­tal back a $26M raise for Realm’s two mid-stage drugs

A promi­nent group of life sci­ences in­vestors has plunked down $26 mil­lion to in­vest in Realm Ther­a­peu­tics, a UK com­pa­ny with a US base that is pur­su­ing a pair of mid-stage stud­ies for atopic der­mati­tis and al­ler­gic con­junc­tivi­tis.

Orig­i­nal­ly named Puri­Core, the com­pa­ny re­or­ga­nized last year and came out gun­ning on a pair of ear­ly-stage drugs: PR022 for atopic der­mati­tis and PR013 for al­ler­gic con­junc­tivi­tis. And they’re go­ing af­ter some hot tar­gets with a new ap­proach us­ing a high con­cen­tra­tion of hypochlor­ous acid to tamp down on a slate of key cy­tokines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER